We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Agena Bioscience

Agena Bioscience is dedicated to advancing the impact of genomics in healthcare and precision medicine with a mission... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Saliva-Based Liquid Biopsy Detects HPV-Caused Head and Neck Cancers

By LabMedica International staff writers
Posted on 27 Sep 2021
Print article
Image: Micrograph image of human papilloma virus associated oropharyngeal cancer (HPV+ OPC). The tissue was stained to show the presence of the virus by in situ hybridization (Photo courtesy of Wikimedia Commons)
Image: Micrograph image of human papilloma virus associated oropharyngeal cancer (HPV+ OPC). The tissue was stained to show the presence of the virus by in situ hybridization (Photo courtesy of Wikimedia Commons)
A saliva-based liquid biopsy assay was developed that might eventually play an essential role in the detection and management of head and neck cancers caused by high-risk human papillomaviruses.

High-risk human papillomavirus (HR-HPV) infection is a major risk factor of head and neck cancers (HNCs). These cancers constitute 3–5% of all malignancies worldwide and there are approximately 600,000 newly diagnosed cases annually. Patients are usually diagnosed at an advanced stage, since in the early stages, these cancers are difficult to locate with imaging studies or physical examination. Furthermore, the oropharynx is difficult to access, and detection is complicated if these smaller lesions are hidden in the crevices of the tonsils. Importantly, these cancers can metastasize at an early stage, even when the primary cancer is still undetectable in size. Despite the rising prevalence of HPV-driven HNC (HPV-HNC) and closely associated oropharyngeal cancers (OPC), biomarkers for detection, prognostication, and disease monitoring are lacking.

Investigators at Queensland University of Technology (Brisbane, Australia) performed a study to evaluate the potential use of salivary HR-HPV DNA as a biomarker of HPV-HNC. For this study, they employed quantitative real-time PCR and the Agena Bioscience (San Diego, CA, USA) MassARRAY system to analyze saliva samples obtained from 491 patients at the time of first diagnosis of HNC and 10 patients with recurring HNC. An additional group of OPC patients was monitored for a period of up to five years.

Results revealed that of the primary-HNC cohort, 43.2% were positive for salivary HR-HPV DNA, with most having OPC. Salivary HR-HPV DNA was detected in 81.4% of tumor p16–positive OPC patients at diagnosis. Salivary HR-HPV–positive patients had a clear survival advantage over their salivary HR-HPV–negative counterparts. The median event-free survivals were 205 months for HR-HPV–positive patients, compared to 82 months for HR-HPV–negative patients.

“Despite the upsurge in HPV-driven HNC, there are no early detection methods or screening strategies for this cancer type, unlike cervical cancer, which is caused by the same virus. Biomarkers enabling early detection, monitoring, and disease prognostication are warranted to combat the rising incidence of HPV-driven OPC,” said senior author Dr. Chamindie Punyadeera, associate professor of biomedical sciences at Queensland University of Technology. “When the noninvasive nature and convenience of the collection are considered, salivary HR-HPV testing is an ideal mode of screening asymptomatic individuals and the long-term monitoring of HPV-driven HNC patients. Our findings indicate that in the near future, salivary HR-HPV testing will become part of routine clinical management for HPV-driven OPC patients.”

The saliva-based biopsy was described in the July 26, 2021, online edition of The Journal of Molecular Diagnostics.

Related Links:
Queensland University of Technology
Agena Bioscience


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.